Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy Authors: Nadine Bast, Karen Dost-Kovalsky, Sabrina Haben, Laura Witt, Ralf Gold, Sandra Thiel, Kerstin Hellwig Published: 2026 ABSTRACT Background and ObjectivesPreliminary data suggest sustained disease control with ocrelizumab (OCR) or rituximab (RTX) in women with multiple sclerosis (MS) after pregnancy suspension; however, the influence of washout duration and cumulative dosing remains unknown. This study investigates disease activity during and after pregnancy in women with relapsing-remitting MS treated with OCR/RTX before pregnancy.MethodsIn this cohort study, pregnancies of women treated with OCR/RTX documented in the German MS and Pregnancy Registry were stratified by timing of last infusion (≥ or <4 months to last menstrual period [LMP]) and number of cycles (≥ or <2 cycles). Relapses treated with high-dose glucocorticosteroids were analyzed, as was persistent disability (following a relapse) at 1-year postpartum, defined as a ≥2.0-point increase in Expanded Disability Status Scale (EDSS) or new/worsening ambulatory impairment (Severe Relapse Disability Composite Score [SRDCS]).ResultsOf 294 pregnancies among 275 women, only 28.6% (n = 84) suspended OCR/RTX ≥4 months before LMP and most (79.3% [n = 233]) received ≥2 cycles. Relapses during pregnancy (2.0%) and within 12 months postpartum (8.5%) were rare. Four women (1.6%) reached the SRDCS postpartum. Neither the time of last infusion nor the number of cycles was associated with a higher relapse risk during pregnancy (time between OCR/RTX and LMP: <4 months adjusted OR: 0.60, CI: 0.09–5.02, p value: 0.60; number of cycles: <2 cycles adjusted OR: 2.23, CI: 0.34–15.5, p value: 0.39) or postpartum (time between OCR/RTX and LMP: <4 months adjusted OR: 0.62, CI: 0.23–1.77, p value: 0.36; number of cycles: <2 cycles adjusted OR: 0.64, CI: 0.16–2.03, p value: 0.48, time of anti-CD20 antibody restart postpartum: >6 weeks adjusted OR: 1.15, CI: 0.37–4.11, p value: 0.82) or with reaching the SRDCS or EDSS worsening postpartum. In women receiving ≥2 cycles and interrupting treatment <4 months before LMP, numerically fewer relapses during pregnancy could be observed (1/163: 0.6% vs 5/131: 3.8%, p value: 0.09).DiscussionRelapses and disability during and after pregnancy after OCR/RTX interruption are rare and independent of timing and number of cycles. However, potential differences may not be detectable due to the low number of events and should be evaluated in larger studies. In addition, the applicability to ofatumumab, given its different dosing interval, remains unclear. Introduction Ocrelizumab (OCR) and rituximab (RTX) are monoclonal antibodies targeting CD20-positive B cells and are used in the treatment of relapsing-remitting multiple sclerosis (RRMS). Owing to their cyclic dosing regimens and long-lasting effects, they seem to offer a favorable profile for disease control during pregnancy and postpartum.1 In contrast to other disease-modifying therapies (DMTs) such as natalizumab or fingolimod—where withdrawal is associated with rebound disease activity2,3—interruption of anti-CD 20 therapies seems to be associated with better disease control.1,4,5 Recommended wash-out periods before conception vary between regulatory agencies: The US Food and Drug Administration currently advises a 12-month interval for RTX and 6-month interval for OCR. Until recently, the European Medicines Agency (EMA) recommended a 12-month wash-out for both agents; however, the guideline for OCR has been revised to a shorter interval of 4 months because of new promising data on pregnancy and neonatal outcomes after pregnancy exposure.4,6,7 These findings suggest that shorter wash-out periods may not increase maternal or neonatal risks,4,6,7 leading many women/neurologists to deviate from official recommendations, with a high proportion conceiving after a shorter than recommended wash-out period.4,6,7 These real-world practices highlight a growing discrepancy between the label in the Summary of Product Characteristics and clinical management. Although recently published data on disease stability after discontinuation of anti-CD20 therapies are encouraging,1,5,8 cohorts were small and did not account for the influence of wash-out duration, number of completed cycles, and timing of restart postpartum, which were the aims of our study. Methods Study Design, Setting, and Participants Pregnancies of women voluntarily enrolled in the German Multiple Sclerosis and Pregnancy Registry (DMSKW)9 between July 11, 2011, and July 11, 2024, were analyzed if the last DMT before pregnancy was either OCR or RTX. Women were excluded from this analysis because of missing enrollment or last menstrual period (LMP) date, lost to follow-up or ongoing pregnancy, unavailable DMT start/stop dates, pregnancy exposure to other DMTs beside OCR/RTX, no RRMS diagnosis, OCR/RTX start during pregnancy, or pregnancy ending in a nonlive birth (Figure 1). Pregnancies were considered retrospective if the enrollment occurred after birth (with no relapses during pregnancy) or if enrollment occurred after a pregnancy-related relapse. Flowchart of Enrolled Pregnancies and Stratification System ARR = annualized relapse rate, DMT = disease-modifying therapy, LMP = last menstrual period; n = number of pregnancies; OCR = ocrelizumab; RRMS = relapsing-remitting MS; RTX = rituximab. * Anti-CD20 antibody start postpartum within 6 weeks and before occurrence of a relapse. ** Anti-CD20 antibody start postpartum after 6 weeks or DMT start postpartum after relapse. Data were collected using standardized, telephone-administered questionnaires at enrollment, during each trimester and 2, 6, and 12 months postpartum.9 Self-reported relapses were confirmed, and Expanded Disability Status Scale (EDSS) scores were obtained from the treating physicians where possible and/or tele-EDSS10 were assessed: (1) within 3 months before pregnancy, (2) during the last trimester of pregnancy, and (3) 12 months postpartum (±7 weeks). In addition, if available from routine measurement, peripartum maternal B-cell counts were collected. In total, 156 of the reported pregnancies were also included in a recent publication on pregnancy and neonatal outcomes.7 Standard Protocol Approvals, Registrations, and Patient Consents The study was approved by the ethics commission Westfalen-Lippe (reference number: 2025-556-f-S), and all participants gave informed consent. Outcomes To assess pregnancy-associated disease activity, the primary outcome was the occurrence of clinically relevant relapses, defined as relapses requiring high-dose glucocorticosteroid treatment. Disability progression was defined as an EDSS increase of at least 1.5 points for a baseline of 0, at least 1 point for a baseline EDSS of 1.0–5.5, or at least 0.5 points for baseline EDSS ≥6.0.11 We additionally used the Severe Relapse Disability Composite Score (SRDCS),2,3 defined as any relapse during pregnancy or postpartum leading to one of the following EDSS increases: (1) EDSS increase of 2 or more points, (2) new ambulatory impairment in participants without significant prepregnancy ambulatory impairment (EDSS increase from ≤3.5 to ≥4.0), or (3) significant worsening ambulatory impairment in those with at least some preexisting ambulatory impairment (EDSS increased from ≤5.5 to ≥6.0, cane or worse, 6.0 to ≥6.5, walker or worse; 6.5 to ≥7.0, wheelchair or worse, 7.0 to ≥8.0, bedbound with some arm function or worse). B cells were defined as detectable at ≥1 cell/µL and within the normal range if absolute counts were ≥90 cells/µL or, when absolute counts were unavailable, if they accounted for ≥6% of lymphocytes. Stratified Groups To assess whether the timing of OCR/RTX interruption influenced pregnancy-associated disease activity, pregnancies were categorized into 2 groups: “≥4 months,” if the last infusion of OCR/RTX before pregnancy was given at least 4 months before the LMP, as currently recommended by the EMA, and “<4 months,” if the last infusion occurred less than 4 months pre-LMP or during pregnancy. To evaluate whether cumulative OCR/RTX exposure was associated with pregnancy-associated disease activity, the cohort was further divided into “≥2 cycles” (e.g., initial cycle 2 × 300 mg OCR and subsequent cycle 1 × 600 mg OCR; e.g., initial cycle 2 × 1,000 mg RTX and subsequent cycle of 1 × 500 mg) and “<2 cycles” (maximum of initial cycle 2 × 300 mg OCR or 2 × 1,000 mg RTX) administered before or up to pregnancy. Postpartum, we stratified pregnancies by timing of anti-CD20 antibody (OCR, RTX or ofatumumab) resumption: “≤6 weeks,” defined as restart of anti-CD20 antibodies within 6 weeks postpartum and before a relapse, and “>6 weeks,” defined as anti-CD20 antibodies restart after 6 weeks up to 12 months postpartum or after a relapse. Statistical Analyses Analyses were conducted using R software (version 4.2.1) and RStudio (version 2023-12.1+402) with a two-sided significance level of α = 0.05. Descriptive statistics are reported as mean (SD) for continuous normally distributed data, median (min-max) for nonparametric continuous data, and number/denominator (percent) (n/N (%)) for categorical data. We compared the stratified groups using t test and ANOVA test for parametric data, Wilcoxon rank-sum test or Kruskal-Wallis test for nonparametric data, χ2 test for binary outcomes (≥5 events), and Fisher exact test (<5 events). We used multivariable logistic regression models to estimate odds ratios (ORs) with 95% CI to assess disease activity during pregnancy and postpartum, restricted to outcomes with a sufficient number of events, adjusted for age at pregnancy onset, body mass index (BMI), disease duration, relapses 1 year prepregnancy, EDSS before pregnancy, and additionally adjusted the postpartum model for relapses during pregnancy, exclusive breastfeeding for at least 2 months, EDSS during pregnancy, and early restart of DMTs postpartum (within 6 weeks after delivery), with covariate correlations assessed. Annualized relapse rates (ARRs) were estimated using multivariable mixed-effects Poisson regression models with a random pregnancy effect to account for the repeated measures approach, with 95% CIs adjusted for age at pregnancy onset, BMI, and disease duration. The observation period was divided into prepregnancy (12 months), pregnancy, and postpartum (12 months). To account for additional adjustments, we further estimated ARRs separately for the pregnancy (relapses 1 year prepregnancy, EDSS before pregnancy) and postpartum periods (relapses 1 year prepregnancy, relapses during pregnancy, EDSS during pregnancy, exclusive breastfeeding for at least 2 months, and early DMT restart (within 6 weeks after delivery)). ARRs were compared as relapse rate ratios (RRRs, 95% CIs) extracted from planned linear contrasts and tested for significant difference using t test. Missing data in outcomes and confounders only minimally reduced group sizes, which is why no imputation was performed. Data Availability Upon reasonable request and in compliance with data protection policies, anonymized data supporting the findings of this study will be shared. Results Baseline Characteristics We identified 294 pregnancies in 275 women in whom the last DMT before pregnancy was either OCR (259 pregnancies) or RTX (35 pregnancies; Figure 1), without significant differences in demographic characteristics (Table 1). Only 9/294 (3.1%) pregnancies were enrolled retrospectively, 3 because of a pregnancy relapse before enrollment. Table 1Characteristics of the Study SampleTotal (n = 294)OCR/RTX suspension before LMP (n = 294)No. of complete cycles before therapy interruption (n = 294)Anti-CD20 antibody restart postpartum (n = 233)≥4 mo (n = 84)<4 mo (n = 210)≥2 cycles (n = 233)<2 cycles (n = 61)≤6 wka (n = 66)>6 wkb (n = 167)Therapy status prior pregnancy ≥2 full cycles233/294 (79.3%)70/84 (83.3%)163/210 (77.6%)NANA53/66 (80.3%)133/167 (79.6%) Ocrelizumab259/294 (88.1%)74/84 (88.1%)185/210 (88.1%)202/233 (86.7%)57/61 (93.4%)57/66 (86.4%)149/167 (89.2%) Therapy suspension before pregnancy264/294 (89.8%)84/84 (100%)180/210 (85.7%)205/233 (88.0%)59/61 (96.7%)59/66 (89.4%)149/167 (89.2%) Last application in weeks, median (min-max)12.6 (0.6–95.3)24.3 (17.4–95.3)8.3 (0.6–17.4)13.0 (0.6–95.3)11.0 (2.0–61.6)11.7 (1.4–41.4)11.9 (0.6–95.3) Therapy suspension in first trimester30/294 (10.2%)0/8430/210 (14.3%)28/233 (12.0%)2/61 (3.3%)7/66 (10.6%)18/167 (10.8%) Therapy duration to last infusion before therapy interruption in weeks, median (min-max)53.7 (0.0–626.0)46.1 (0.0–246.9)54.4 (0.0–626.0)61.0 (21.3–626.0)2.0 (0.0–7.3)66.2 (0–213.6)53.7 (0–626)Demographic characteristics Age at LMP, mean (SD)32.7 (3.8)32.6 (3.7)32.7 (3.8)32.7 (3.7)32.6 (4.0)32.5 (3.3)32.7 (3.8) Prospective enrollmentc285/294 (96.9%)80/84 (95.2%)205/210 (97.6%)226/233 (97.0%)59/61 (96.7%)62/66 (93.9%)164/167 (98.2%) GW at enrollment, median (min-max)8.0 (3.4–39.4)8.4 (4.0–39.4)8.0 (3.4–39.0)8.0 (3.6–39.4)9.3 (3.4–39.0)9.0 (4.0–32.3)7.8 (3.4–39.4) BMI in kg/m2, mean (SD)24.3 (5.2)24.2 (5.1)24.3 (5.3)24.2 (5.0)24.7 (6.0)23.9 (4.9)24.2 (5.3) Smoking during pregnancy4/294 (1.4%)1/84 (1.2%)3/210 (1.4%)2/233 (0.9%)2/61 (3.3%)1/66 (1.5%)2/167 (1.2%) Disease duration at conception, y, median (min-max)7.4 (0.2–23.9)7.0 (0.9–20.0)7.8 (0.2–23.9)7.4 (0.5–23.9)7.7 (0.2–19.0)7.4 (0.7–19.0)7.6 (0.2–22.1) Relapse in the year before pregnancy55/294 (18.7%)14/84 (16.7%)41/210 (19.5%)33/233 (14.2%)22/61 (36.1%)12/66 (18.2%)33/167 (19.8%) No. of relapses, median (min-max)0 (0–4)0 (0–3)0 (0–4)0 (0–3)0 (0–4)0 (0–4)0 (0–4) After anti-CD20 antibody therapy start31/294 (10.5%)11/84 (13.1%)20/210 (9.5%)26/233 (11.2%)5/61 (8.2%)9/66 (13.6%)17/167 (10.2%) EDSS prepregnancy, median (min-max)2 (0–7.5)2 (0–6.5)2 (0–7.5)2 (0–7.5)2 (0–7)2 (0–7)2 (0–7.5) Missing4312202Postpartum disease management DMT restart in the first year postpartum237/294 (80.6%)60/84 (71.4%)177/210 (84.3%)188/233 (80.7%)49/61 (80.3%)66/66 (100%)167/167 (100%) Anti-CD20 antibodies233/294 (79.3%)58/84 (69.0%)175/210 (83.3%)186/233 (79.8%)47/61 (77.0%)66/66 (100%)167/167 (100%) Ocrelizumab167/233 (71.7%)38/58 (65.5%)129/175 (73.7%)129/186 (69.4%)38/47 (80.9%)44/66 (66.7%)123/167 (73.7%) Rituximab24/233 (10.3%)6/58 (10.3%)18/175 (10.3%)23/186 (12.4%)1/47 (2.1%)13/66 (19.7%)29/167 (17.4%) Ofatumumab42/233 (18.0%)14/58 (24.1%)28/175 (16.0%)34/186 (18.3%)8/47 (17.0%)9/66 (13.6%)15/167 (9.0%) Other DMTd4/294 (1.4%)2/84 (2.4%)2/210 (1.0%)2/233 (0.9%)2/61 (3.3%)NANA Anti-CD20 antibody start postpartum ≤6 wk and before occurrence of a relapse66/294 (22.4%)14/84 (16.7%)52/210 (24.8%)53/233 (22.7%)13/61 (21.3%)NANA Anti-CD20 antibody start postpartum >6 wk, or after a relapse167/294 (56.8%)44/84 (52.4%)123/210 (58.6%)133/233 (57.1%)34/61 (55.7%)NANA Timing of restart after birth in weeks, median (min-max)14.0 (3.7–52.0)13.9 (6.4–51.9)14.0 (3.7–52.0)13.9 (3.7–52.0)14.4 (6.1–48.0)NA14.0 (3.7b-52.0) Therapy break between last OCR/RTX before LMP and restart postpartum in weeks, median (min-max)62.1 (37.4–143.3)77.9 (60.0–143.3)56.3 (37.4–101.7)62.1 (37.4–143.3)61.0 (44.0–140.4)53.3 (37.9–83.7)67.1 (37.4–143.3) Exclusive breastfeeding, n (%)e124/294 (42.2%)40/84 (47.6%)84/210 (40.0%)104/233 (44.6%)20/61 (32.8%)23/66 (34.8%)75/167 (44.9%) Breastfeeding with DMT exposure63/124 (50.8%)19/40 (47.5%)44/84 (52.4%)55/104 (52.9%)8/20 (40.0%)23/23 (100%)40/75 (53.3%) 12-mo follow-up postpartum248/294 (84.4%)71/84 (84.5%)177/210 (84.3%)193/233 (82.8%)55/61 (90.2%)53/66 (80.3%)152/167 (91.0%)Abbreviations: BMI = body mass index; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; GW = gestational week; LMP = last menstrual period; max = maximum; min = minimum; mo = months; OCR = ocrelizumab; RTX = rituximab, wk = weeks.aAnti-CD20 antibody start postpartum within 6 wk and before occurrence of a relapse.bAnti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse.cStudy entry before first relapse during pregnancy and before end of pregnancy.dIncluding fingolimod, dimethyl fumarate, and peginterferon-beta.eExclusive breastfeeding is defined as breastfeeding without supplemental feedings for at least 2 mo. Characteristics of the Study Sample Abbreviations: BMI = body mass index; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; GW = gestational week; LMP = last menstrual period; max = maximum; min = minimum; mo = months; OCR = ocrelizumab; RTX = rituximab, wk = weeks. Anti-CD20 antibody start postpartum within 6 wk and before occurrence of a relapse. Anti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse. Study entry before first relapse during pregnancy and before end of pregnancy. Including fingolimod, dimethyl fumarate, and peginterferon-beta. Exclusive breastfeeding is defined as breastfeeding without supplemental feedings for at least 2 mo. Most women received at least 2 complete cycles (233/294: 79.3%) of OCR or RTX and suspended their treatment less than 4 months before pregnancy onset (210/294 71.4%), with 14.3% (30/210) receiving the last infusion prior interruption after the LMP in median gestational week 2.4 (0–9.6). The median therapy duration with OCR/RTX in the whole cohort was 68.4 (0.1–635.4) weeks until pregnancy. Among women who received fewer than 2 complete cycles of OCR/RTX, relapses in the year before pregnancy were more common (22/61: 36.1%) compared with those who received at least 2 cycles (33/233: 14.2%; p value: <0.001) (Table 1). Postpartum Disease Management The median therapy break duration between the last infusion of OCR/RTX before/during pregnancy and anti-CD20 antibody restart postpartum was median 62.1 week (range: 37.4–143.4 weeks). Only 66/294 (22.4%) women restarted an anti-CD20 antibody treatment within 6 weeks postpartum. The majority resumed treatment between 6 weeks and 12 months postpartum (166/294: 56.5%), 1 woman after a relapse within the first 6 weeks postpartum (1/294: 0.3%). OCR was used the most (167/233: 71.7%), followed by ofatumumab (42/233: 18.0%) and RTX (24/233: 10.3%). By contrast, 20.7% (61/294) did not restart any anti-CD20 antibody treatment within the first year after delivery, only 4 (4/294: 1.4%) women chose another DMT postpartum (fingolimod (n = 2), dimethyl fumarate (n = 1), or peginterferon-beta (n = 1)). One hundred twenty-four women (42.2%) decided to breastfeed exclusively, 51.6% (64/124) restarted a DMT (all anti-CD20 antibodies) while breastfeeding (Table 1). In total, 248/294 (84.4%) pregnancies were followed up for at least 12 months postpartum, more with late anti-CD20 antibody restart postpartum (>6 weeks: 152/167: 91.0% vs ≤6 weeks 53/66: 80.3%, p value: 0.04). Relapse Activity During Pregnancy and Postpartum Overall, only 6/294 women (2.0%) had a relapse with high-dose glucocorticosteroid treatment during pregnancy, one with an additional immunoadsorption, receiving her first and only OCR cycle (2 × 300 mg) 67 days before LMP (Table 2, eTable 1). This patient experienced 4 relapses within the year before pregnancy and was treated with dimethyl fumarate before OCR. Time to relapse after the last OCR/RTX infusion ranged from 16 to 67 weeks (eTable 1). Although relapses during pregnancy occurred numerically more often in women with less than 2 cycles (4.9%, 3/61 vs ≥2 cycles: 1.3%, 3/233, p value: 0.11) and in women with their last OCR/RTX treatment more than 4 months before pregnancy (2/84, 2.4% vs <4 months: 4/210, 1.9%, p value: 1), no increased risks were observed in the adjusted regression analyses (time between OCR/RTX and LMP: <4 months adjusted OR: 0.60, CI: 0.09, 5.02, p value: 0.60; number of cycles: <2 cycles adjusted OR: 2.23, CI: 0.34, 15.5, p value: 0.39) (Table 3). Table 2Disease Activity During PregnancyTotal (n = 294)OCR/RTX suspension before LMPNo. of complete cycles before therapy interruption≥4 mo (n = 84)<4 mo (n = 210)p Value≥2 cycles (n = 233)<2 cycles (n = 61)p ValueRelapse during pregnancya6/294 (2.0%)2/84 (2.4%)4/210 (1.9%)1b3/233 (1.3%)3/61 (4.9%)0.11b Thereof <2 cycles3/6 (50%)0/23/4 (75%)NANANANA Thereof ≥2 cycles3/6 (50%)2/2 (100%)1/4 (25%)NANANANA 1. Trim2/294 (0.7%)1/84 (1.2%)1/210 (0.5%)0.49b1/233 (0.4%)1/61 (1.6%)0.37b 2. Trim4/294 (1.4%)1/84 (1.2%)3/210 (1.4%)1.00b2/233 (0.9%)2/61 (3.3%)0.19b 3. Trim0/2940/840/210NA0/2330/61NANo. of relapses during pregnancy, median (min-max)0 (0–2)0 (0–2)0 (0–1)0.79c0 (0–2)0 (0–1)0.08cImmunoadsorption1/294 (0.3%)0/841/210 (0.5%)1b0/2331/61 (1.6%)0.21bEDSS during pregnancy, median (min-max)2 (0–7.5)2 (0–7.5)2 (0–7.5)0.86c2 (0–7.5)2 (0–6)0.47c Missing431na22na No disability (EDSS 0–2.0)191/290 (65.9%)54/81 (66.7%)137/209 (65.6%)0.98d153/231 (66.2%)38/59 (64.4%)0.73d Some disability (EDSS 2.5–3.5)86/290 (29.7%)24/81 (29.6%)62/209 (29.7%)0.98d67/231 (29.0%)19/59 (32.2%)0.84d Some ambulatory impairment, no assist device (EDSS 4.0–5.5)9/290 (3.1%)2/81 (2.4%)7/209 (3.3%)1b7/231 (3.0%)2/59 (3.4%)1b Cane required (EDSS 6.0–6.5)2/290 (0.7%)0/812/209 (1.0%)1b2/231 (0.9%)0/591b Wheelchair required (EDSS ≥7.0)2/290 (0.7%)1/81 (1.2%)1/209 (0.5%)0.49b2/231 (0.9%)0/591bDisability progression during pregnancye7/290 (2.4%)2/81 (2.4%)5/209 (2.4%)1b5/231 (2.2%)2/59 (3.4%)0.63bSevere relapse disability composite score (SRDCS) in pregnancy, n(%)1/290 (0.3%)1/81 (1.2%)0/2090.28b1/231 (0.4%)0/591bAbbreviations: DMT = disease-modifying therapy, EDSS = Expanded Disability Status Scale, LMP = last menstrual period, max = maximum, min = minimum, mo = months, Trim = trimenon.aRelapses requiring at least high-dose glucocorticosteroid treatment.bFisher exact test.cWilcoxon rank-sum test.dChi-square test.eDefined as. Disease Activity During Pregnancy Abbreviations: DMT = disease-modifying therapy, EDSS = Expanded Disability Status Scale, LMP = last menstrual period, max = maximum, min = minimum, mo = months, Trim = trimenon. Relapses requiring at least high-dose glucocorticosteroid treatment. Fisher exact test. Wilcoxon rank-sum test. Chi-square test. Defined as. Table 3Relapses During Pregnancy and 12 Months Postpartum Crude/Adjusted Logistic Regression ModelOR95% CIp ValueOR95% CIp ValueCrudeAdjustedRelapses during pregnancya OCR/RTX suspension before LMP ≥4 moReference categoryReference category <4 mo0.800.15–5.820.790.600.09–5.020.60 No. of complete cycles before therapy interruption ≥2 cyclesReference categoryReference category <2 cycles3.970.72–21.90.102.230.34–15.50.39Relapses during the first year postpartum OCR/RTX suspension before LMPb ≥4 moReference categoryReference category <4 mo0.690.30–1.690.390.620.23–1.770.36 No. of complete cycles before therapy interruptionb ≥2 cyclesReference categoryReference category <2 cycles0.710.20–1.950.540.640.16–2.030.48 Anti-CD20 antibody restart postpartumc ≤6 wkeReference categoryReference category >6 wkf1.130.45–3.270.801.150.37–4.110.82Disability progression postpartum OCR/RTX suspension before LMPb ≥4 moReference categoryReference category <4 mo1.280.43–4.680.681.300.43–4.850.67 No. of complete cycles before therapy interruptionb ≥2 cyclesReference categoryReference category <2 cycles0.720.16–2.290.610.620.13–2.200.50 Anti-CD20 antibody restart postpartumd ≤6 wkeReference categoryReference category >6 wkf0.700.23–2.320.520.660.20–2.550.51Abbreviations: CI = confidence interval, DMT = disease-modifying therapy, LMP = last menstrual period, mo = months, n = number of participant with outcome, OCR = ocrelizumab, OR = odds ratio, RTX = rituximab, wk = weeks.Binary logistic regression models were used to estimate ORs.aAdjusted for age, body mass index (BMI), disease duration, relapse 1 year prepregnancy, and Expanded Disability Status Scale (EDSS) before pregnancy.bAdjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, exclusive breastfeeding for at least 2 months, and early restart (within 6 wk after delivery).cAdjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, exclusive breastfeeding for at least 2 months, and 12-month follow-up.dAdjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, and exclusive breastfeeding for at least 2 months.eAnti-CD20 antibody start postpartum within 6 wk and before occurrence of a relapse.fAnti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse. Relapses During Pregnancy and 12 Months Postpartum Crude/Adjusted Logistic Regression Model Abbreviations: CI = confidence interval, DMT = disease-modifying therapy, LMP = last menstrual period, mo = months, n = number of participant with outcome, OCR = ocrelizumab, OR = odds ratio, RTX = rituximab, wk = weeks. Binary logistic regression models were used to estimate ORs. Adjusted for age, body mass index (BMI), disease duration, relapse 1 year prepregnancy, and Expanded Disability Status Scale (EDSS) before pregnancy. Adjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, exclusive breastfeeding for at least 2 months, and early restart (within 6 wk after delivery). Adjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, exclusive breastfeeding for at least 2 months, and 12-month follow-up. Adjusted for age, BMI, relapse 1 year prepregnancy, relapse during pregnancy, disease duration, EDSS during pregnancy, and exclusive breastfeeding for at least 2 months. Anti-CD20 antibody start postpartum within 6 wk and before occurrence of a relapse. Anti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse. When combining a short interval (<4 months) between anti-CD20 antibody suspension and LMP with the receipt of at least 2 complete cycles, we observed a trend toward fewer relapses during pregnancy (1/163: 0.6%) compared with an interval of ≥4 months and fewer than 2 cycles (5/131: 3.8%; p value: 0.09). During the postpartum period, 25/294 (8.5%) women had a relapse, 1.0% (3/294) within the first 28 days after delivery and 12/294 (4.1%) before DMT restart (Table 4). Women receiving their last infusion of OCR/RTX less than 4 months before LMP showed a lower postpartum relapse risk compared with women who stopped their treatment more than 4 months before LMP, without reaching statistical significance (adjusted OR: 0.62, CI: 0.24–1.69, p value: 0.33) (Tables 3 and 4). Table 4Disease Activity PostpartumTotal (n = 294)OCR/RTX suspension before LMPNo. of complete cycles before therapy interruptionAnti-CD20 antibody restart postpartum (n = 233)≥4 mo (n = 84)<4 mo (n = 210)p Value≥2 cycles (n = 233)<2 cycles (n = 61)p Value≤6 wka (n = 66)>6 wkb (n = 167)p ValueRelapses within the first year postpartum25/294 (8.5%)9/84 (10.7%)16/210 (7.6%)0.53e21/233 (9.0%)4/61 (6.6%)0.80f6/66 (9.1%)17/167 (10.2%)1e In women with 12-mo follow-up24/248 (9.7%)8/71 (11.3%)16/177 (9.0%)0.77e20/193 (10.4%)4/55 (7.3%)0.61f6/53 (11.3%)16/152 (10.5%)1eRelapses before anti-CD20 antibody restart within the first year postpartum12/294 (4.1%)5/84 (6.0%)7/210 (3.3%)0.33f10/233 (4.3%)2/61 (3.3%)1f0/6610/167 (6.0%)naNo. of relapses postpartum, median (min-max)0 (0–2)0 (0–2)0 (0–2)0.37g0 (0–2)00.56g0 (0-2)0 (0-2)0.85g Relapse within the first 28 d postpartum3/294 (1.0%)1/84 (1.2%)2/210 (1.0%)1f3/233 (1.3%)0/611f0/663/168 (1.8%)0.56f Relapse within the first trimester postpartumc8/280 (2.9%)3/80 (3.8%)5/200 (2.5%)0.69f6/223 (2.7%)2/57 (3.5%)0.67f4/62 (6.5%)4/165 (2.4%)0.22f Relapse within the second trimester postpartumc9/271 (3.3%)4/76 (5.3%)5/195 (2.6%)0.27f8/214 (3.7%)1/57 (1.8%)0.69f2/61 (3.3%)6/159 (3.8%)1f Relapse within the third trimester thirdc5/249 (2.0%)2/71 (2.8%)3/178 (1.7%)0.63f4/193 (2.1%)1/56 (1.8%)1f1/54 (1.9%)3/152 (2.0%)1f Relapse within the fourth trimester postpartumd4/248 (1.6%)0/714/177 (2.3%)0.58f4/193 (2.1%)0/550.58f1/53 (1.9%)3/152 (2.0%)1fEDSS postpartum, median (min-max)2 (0–7.5)2 (0–7.5)2 (0–7.5)0.89g2 (0–7.5)2 (0–6.5)0.90g2 (0–7.5)2 (0–6.5)0.20g Missing471532na425na1216na No disability (EDSS 0–2.0)164/247 (66.4%)47/69 (68.1%)117/178 (65.7%)1e128/191 (67.0%)36/56 (64.3%)0.67e31/54 (57.4%)104/151 (68.9%)0.05e Some disability (EDSS 2.5–3.5)72/247 (29.1%)20/69 (29.0%)52/178 (29.2%)0.98e55/191 (28.8%)17/56 (30.4%)0.60e20/54 (37.0%)42/151 (27.8%)0.53e Some ambulatory impairment, no assist device (EDSS 4.0–5.5)5/247 (2.0%)1/69 (1.4%)4/178 (2.2%)1f3/191 (1.6%)2/56 (3.6%)0.28f1/54 (1.9%)3/151 (2.0%)1f Cane required (EDSS 6.0–6.5)4/247 (1.6%)0/694/178 (2.2%)0.58f3/191 (1.6%)1/56 (1.8%)1f1/54 (1.9%)2/151 (1.3%)1f Wheelchair required (EDSS ≥7.0)2/247 (0.8%)1/69 (1.4%)1/178 (0.6%)0.49f2/191 (1.0%)0/561f1/54 (1.9%)0/1510.28fDisability progression between before pregnancy and postpartum17/247 (6.9%)4/69 (5.7%)13/178 (7.3%)0.80f14/191 (7.3%)3/56 (5.4%)0.80f5/54 (9.3%)10/151 (6.6%)0.55fSevere Relapse Disability Composite Score (SRDCS) postpartum4/247 (1.6%)2/69 (2.9%)2/178 (1.1%)0.30f3/191 (1.6%)1/56 (1.8%)1f3/54 (5.6%)1/151 (0.7%)0.06fAbbreviations: EDSS = Expanded Disability Status Scale, max = maximum, min = minimum, mo = months, OCR = ocrelizumab, RTX = rituximab, wk = weeks.Postpartum disease activity in women with at least 3-mo follow-up.aAnti-CD20 antibody start within 6 wk and before occurrence of a relapse.bAnti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse.cFollow-up at least until end of trimester.dWith 12-month follow-up.eChi-square test.fFisher exact test.gWilcoxon rank-sum test. Disease Activity Postpartum Abbreviations: EDSS = Expanded Disability Status Scale, max = maximum, min = minimum, mo = months, OCR = ocrelizumab, RTX = rituximab, wk = weeks. Postpartum disease activity in women with at least 3-mo follow-up. Anti-CD20 antibody start within 6 wk and before occurrence of a relapse. Anti-CD20 antibody start postpartum after 6 wk or anti-CD20 antibody start postpartum after relapse. Follow-up at least until end of trimester. With 12-month follow-up. Chi-square test. Fisher exact test. Wilcoxon rank-sum test. Six MS-patients with anti-CD20 antibody restart ≤6 weeks postpartum experienced a relapse within 12 months postpartum (6/66: 9.1%; adjusted ARR: 0.07, CI: 0.03–0.19), whereas in those who restarted anti-CD20 antibodies later (n = 166), or initiated treatment ≤6 weeks postpartum but after a relapse (n = 1), 17 women had relapses postpartum (17/167: 10.2%; adjusted ARR: 0.06, CI: 0.03-0-13; adjusted OR vs ≤6 weeks: 0.66; CI: 0.20–2.55, p value: 0.51; adjusted RRR vs ≤6 weeks: 0.80, CI: 0.33–1.91, p value: 0.61). Neither the timing of suspension before the LMP, the number of complete cycles, nor the timing of DMT reinitiation postpartum led to significant difference in relapse activity postpartum, as determined by both descriptive and regression analysis (Tables 3 and 4). In women not restarting anti-CD20 antibodies within the first 12 months postpartum, only 2 (2/61: 3.3%) had postpartum relapses. In adjusted Poisson regression analyses, across all stratified groups, the ARR was highest during the prepregnancy period, declined to <0.1 during pregnancy, and remained below prepregnancy levels throughout the first postpartum year (Figure 2). Overall, ARRs remained consistently low in all groups, and no significant differences between the stratified groups were observed during pregnancy or the postpartum period using relapse rate ratios (RRRs, 95% confidence interval) estimated from linear contrasts (eTable 2). Annualized Relapse Rates (ARR) Prepregnancy, During Pregnancy, and Postpartum (A) Stratified by timing of last OCR/RTX before LMP, (B) number of complete cycles before therapy interruption. LMP = last menstrual period; OCR = ocrelizumab; RTX = rituximab. Although an association could not be assessed between relapses before and during pregnancy because of the low number of events, no association was found between postpartum relapses and relapses either before (OR: 1.04, CI: 0.31, 3.15, p value: 0.94) or during pregnancy (OR: 1.57, CI: 0.04, 25.8, p value: 0.78; eTable 3). In women with relapses postpartum, the median therapy break duration was insignificantly (p value: 0.14) longer (65.6 weeks [range: 37.9–131.0]) than in women without relapses postpartum (61.4 weeks, range: 37.4–143.3). A higher EDSS during pregnancy was associated with a higher relapse risk postpartum (OR: 1.50, CI: 1.13, 2.03, p value: 0.007), and relapses postpartum were decreased in pregnancies of women exclusively breastfeeding for at least 2 months (OR: 0.27, CI: 0.07, 0.81, p value: 0.030; eTable 3). Disability Progression Baseline and pregnancy EDSS scores were available in 290/294 (98.6%) pregnancies. At baseline, 3 women required a wheelchair and 3 women required a cane, but most women (174/290: 60.0%) had little disability before pregnancy onset with a median EDSS of 2.0 (min-max: 0–7.5) (eTable 1). Disability progression during pregnancy occurred in 7/290 (2.4%) and the severe relapse disability composite score was reached in only 1/290 (0.3%) pregnancy, with an EDSS increase from 6.5 to 7.5 (Table 2). No significant differences were found between the stratified groups regarding disability progression or SRDCS, but the low number of events precluded regression analyses for these outcomes. As shown in Figure 3, negative MS disease outcomes (relapses, disability progression, and SRDCS) postpartum were rare. EDSS postpartum was available in 84.0% (247/294) of pregnancies. Seventeen women (17/247; 6.9%) with available EDSS scores experienced disability progression between baseline and 12 months postpartum (Table 4 + Figure 3). Disability progression occurred numerically more often in women with OCR/RTX suspension less than 4 months before LMP (adjusted OR: 1.30, CI: 0.43, 4.85, p value: 0.67), and less often in women with <2 cycles OCR/RTX (adjusted OR: 0.62, CI 0.13, 2.20, p value: 0.50) and in women with a late anti-CD20 antibody restart postpartum (adjusted OR: 0.66, CI: 0.20, 2.55, p value: 0.51), but the observed differences were not statistically significant in the regression analyses (Table 3). Icon Array Representing the Proportion of Women Having At Least 1 Relapse, Disability Progression or Reaching the Severe Relapse Disability Composite Score (SRDCS) in the First Year Postpartum Per 100 Pregnancies Four (4/247: 1.6%) women reached the SRDCS postpartum with EDSS increases from 6.5 to 7.5, from 3.5 to 4.0, from 0 to 2.5, and from 0 to 2.0 without statistically significant differences between the stratified groups (Figure 3, Table 4). B-Cell Counts During Pregnancy and Postpartum B-cell counts were available for 65 of 294 pregnancies (22.1%) during pregnancy and/or postpartum. In 46 women with available samples before or during pregnancy, 40 samples were obtained a median of 247.5 days (range: 60–474) after the last OCR/RTX infusion and a median of 104 days (range: 8–376) before delivery. In total, 24/40 (60%) had detectable B cells (at least 1/µL), of which 29.2% (7/24) were within the normal range (at least 90/µL or if not available: at least 6%). In total, 16/40 women (40%) had no detectable B cells at a median of 174 days (range: 32–311) before birth. In 2 women who experienced a relapse during pregnancy and had available B-cell measurements, B cells were not detectable at the time of relapse (±2 days) in one woman and depleted (1/µL; 0.1%) in the other woman (eTable 1). In 38 women with available postpartum samples, 30 samples were collected before the reinitiation of anti-CD20 antibody therapy, at a median of 30.2 (0–373) days after delivery. Among them, 29/30 (96.7%) had detectable B cells, of which 34.5% (10/29) fell within the normal range. In 3 women who experienced a postpartum relapse and had available B cells postpartum, B cells were detectable at a median of 51–149 days before relapse in all women, and 1 of 3 fell within the normal range (eTable 1, No 2+3). Discussion This pregnancy cohort study represents a large data set on disease activity during and after pregnancy of women with MS who conceived after OCR/RTX treatment (n = 294) and adds important knowledge for women with highly active diseases planning a pregnancy. Relapse rates during pregnancy and postpartum, as well as disability progression or functionally relevant disability by reaching the SRDCS, were rare. Most women (288/294: 98.0%) remained relapse free during pregnancy and/or postpartum (269/294: 91.5%), although the median therapy break between OCR/RTX suspension and postpartum treatment restart was 62.1 week. Overall, only 4 women developed sustained disability after a relapse (SRDCS; 1.6%). Although we found numerically higher relapse rates in women with only 1 full cycle of OCR/RTX during pregnancy (3/61: 4.9%, vs 6/294: 2.0% in total), in the adjusted models, neither the number of cycles nor the timing of suspension were statistically significant associated with relapses during pregnancy. Of note, we did not observe statistically significant associations between relapses (in total: 25/294: 8.5%) or disability progression postpartum (in total: 17/247: 6.9%), and the number of OCR/RTX infusions received before pregnancy, the timing of treatment interruption before conception, or the timing of DMT reinitiation postpartum, but exclusive breastfeeding for at least 2 months was associated with a lower relapse risk postpartum in the whole cohort. Our observed low number of relapses during pregnancy (2.0%) and postpartum (8.5%) is consistent with previous studies reporting sustained disease control in women treated with anti-CD20 therapies before conception.5,12-14 Several smaller cohorts (n = 2114; n = 7612) have demonstrated low relapse occurrence during pregnancy (RTX: 0.0%5-1.3%,12 OCR: 0%,5 RTX/OCR: 3%13) and postpartum (RTX: 5.3%12-12.4%,5 OCR: 4.1%,5 RTX/OCR: 0%13) after preconception treatment with OCR or RTX, supporting the concept of prolonged clinical effects beyond the dosing interval. Disability progression in the first year postpartum in other cohorts was rare (OCR/RTX: 0%,13 OCR/RTX: EDSS conception 2.0 [1.0–2.5] vs EDSS postpartum 2.0 [1.5–3.0]14). We also observed generally stable disability levels with a median EDSS of 2 (0–7.5) at conception and 2 (0–7.5) postpartum, but 6.9% of pregnancies in our cohort showed disability progression postpartum. This discrepancy with earlier findings may be explained by differences in cohort size because our study included substantially more pregnancies (n = 247) than the previously reported cohort (n = 33)13 and included more participants with higher disability at baseline (EDSS at baseline: our cohort: 2 (0–7.5); Demortiere, et al.: 1 (0–4)13). Another important finding of this study was that neither the cumulative number of infusions nor the precise timing of the last infusion (leading to longer therapy breaks) before pregnancy seems to critically influence short-term disease outcomes during and after pregnancy. Sustained disease stability despite extended dosing intervals of ocrelizumab and rituximab has been well documented in nonpregnant populations,15-19 with disease stability maintained up to a median therapy break of 28.5 months, while reactivation risk increased after more than 32 months off-treatment.19 In our cohort, the median therapy break between OCR/RTX interruption because of pregnancy and postpartum treatment restart was 62.1 week (range: 37.4–143.3 weeks), thus largely falling within the time frame in which disease stability has previously been observed after treatment discontinuation.19 However, the precise duration of this carry-over effect is still unknown, and the minimal number of cycles required to achieve sustained disease stability after a therapy withdrawal remains unclear, particularly in the context of pregnancy. To date, the relevance of the number of anti-CD20 cycles before treatment discontinuation has only been investigated in a small study of nonpregnant patients.20 After 2 cycles of ocrelizumab (2 × 300 mg plus 1 × 600 mg) and follow-up for up to 46 months, disease reactivation occurred in 32% of patients (6/19), no earlier than 19 months after the last infusion, and was limited to radiologic findings. In a propensity score–matched standard interval dosing control group (n = 52), no disease reactivation was observed. Restricted mean survival time to disease reactivation was modestly shorter with finite dosing than with standard interval dosing (40.5 vs 46.0 months; p = 0.011); however, disease reactivation occurred late in the observation period in both groups, indicating prolonged disease stability even after receiving only 2 cycles of ocrelizumab or rituximab.20 The treatment effect after only a single cycle of OCR/RTX has not yet been studied. In our cohort, we observed a numerically higher relapse rate during pregnancy among women who had received only 1 cycle of OCR/RTX (4.9% vs ≥2 cycles: 1.3%, p value: 0.11). Of note, only 4 women experienced a relapse within the first 12 months postpartum (4/61: 6.6%), which was even fewer than among women who had received ≥2 cycles before pregnancy (21/233: 9.0%); unlike observations in natalizumab-treated patients, where disease control is dependent on continuous treatment, with longer therapy duration—and consequently greater cumulative exposure.2 Other disease-modifying therapies used in the treatment of MS also demonstrate that durable disease control can be achieved with a limited number of treatment courses, as shown for immune reconstitution therapies such as alemtuzumab21 and cladribine.22 In line with this concept, our findings suggest that a finite number of ocrelizumab infusions before pregnancy—potentially even a single cycle—may be sufficient to maintain disease suppression throughout pregnancy and postpartum. However, as we observed an association between disability during pregnancy (or preconception) and disease activity postpartum, further research is needed to determine whether patients with higher baseline activity might benefit from a more prolonged treatment duration before conception as we observed by combining a short interval (<4 months) between OCR/RTX suspension before pregnancy in combination with at least 2 cycles OCR/RTX we observed numerically fewer relapses during pregnancy (1/163: 0.6% vs 5/131: 3.8%, p value: 0.09), but not postpartum. These findings should be interpreted within the context of an overall low event rate, which limited the statistical power, but may become more evident in future studies as cohorts grow—driven by the increasing use of anti-CD20 therapies (including newer agents such as ofatumumab or ublituximab) during childbearing years. Notably, our data indicate that the timing of treatment resumption should be tailored to preconception and pregnancy disability, and we also observed a protective effect of exclusive breastfeeding against postpartum relapses, which has also been described in previous studies.23 This observation together with the well-established health benefits of breastfeeding for mother24 and child25 supports recommendations to encourage breastfeeding whenever possible. For many patients, the prolonged efficacy of prior anti-CD20 treatment may provide a safe clinical window to pursue breastfeeding before transitioning back to anti-CD20 antibodies if they do not wish to breastfeed under DMT exposure. Breastfeeding during treatment with anti-CD20 antibodies is now supported by the European label26,27; in our cohort, around half of breastfeeding patients (63/124, 50.8%) combined both. Available B-cell counts were heterogeneous, and relapses occurred even in 2 women with complete peripheral B-cell depletion and did not occur in most women who had detectable B cells. Other studies also found that peripheral CD19+ B-cell repopulation might not reliably predict disease reactivation neither in the form of relapses28 nor MRI activity20 and that B-cell repopulation dynamics exhibit high interindividual variability and differ substantially between total B cells and memory B cells.18 This observation suggests that total peripheral B-cell reconstitution alone may not be a sufficient biomarker for relapse risk assessment during pregnancy and postpartum. From a clinical perspective, our findings support the notion that anti-CD20 therapies administered before pregnancy are associated with favorable maternal disease control, both during pregnancy and postpartum. Given the growing evidence for fetal safety even when anti-CD20 antibodies are interrupted shortly before or after conception,6,7 these agents seem to represent valuable options for women with active disease course planning a pregnancy. By contrast, other DMTs considered for highly active disease are associated with notable limitations: withdrawal of natalizumab at pregnancy onset carries a high risk of relapse (22.9% during pregnancy, 49.7% postpartum, and 10.0%SRDCS postpartum),2 and exposure during pregnancy may lead to hematologic abnormalities.29 Fingolimod, similarly, is linked to high relapse rates after withdrawal (31.5% during pregnancy, 44.6% postpartum, and 6.3%SRDCS postpartum)3 and carries a risk for congenital anomalies if used during pregnancy planning.30 The strength of this study lies in its large cohort size, which allowed stratification across different treatment strategies within the same drugs and could not been analyzed in previous studies. In addition, the design of the German MS and Pregnancy Registry ensures a close prospective follow-up and detailed examination of disease outcomes with adjustment for various confounders, which enhanced the generalizability and analytical robustness of the findings. However, several limitations warrant consideration. Most notably, the low number of relapses and disability events constrained statistical analyses and may have obscured subtle associations. In addition, B-cell measurements were not available for all pregnancies and were not standardized with respect to timing. No MRI data were available for this cohort, and disability was assessed using EDSS scores, which were clinician administered when available, but self-reported otherwise. Although clinician-assessed EDSS is the gold standard for measuring disability, self-reported measures have been shown to approximate clinical categorizations reasonably well in MS research and are useful when formal assessments are not available.31 Finally, the observational nature of the study limits causal inference. Larger sample size is needed to more precisely define the influence of cumulative dosing, optimal timing of the last anti-CD20 infusion relative to the LMP, and the best time point of postpartum treatment reinitiation, especially in women with aggressive disease. In addition, future research should investigate whether extended dosing intervals or reduced dosages could mitigate known side effects, such as an increased susceptibility to infections, whether the reported findings extend to other anti-CD20 antibodies with different dosing regimens (e.g., ofatumumab), and should further compare different DMT strategies, including withdrawal of first-line therapies, regarding postpartum relapses and disability progression.